Hi, I'm Sarfaraz A. Khan. I have got an MBA from University of Aberdeen, located in the heart of UK's oil industry. My specialties lie in energy and materials stocks, but I occasionally cover services sector, emerging markets and ETFs. My work appears mainly on TheStreet and Seeking Alpha.
I am not based in the US, which is why I do not have any position in the US listed stocks that I write about. I do, however, own shares of funds that usually hold a long position in either Exxon Mobil, Chevron, Royal Dutch Shell, Schlumberger, Halliburton, ConocoPhillips, Honda Motor Company, GlaxoSmithKline, Unilever, or their subsidiaries that trade on non-US markets.
EP Vantage is a forward-looking comment and analysis service tailored to the needs of pharma and finance professionals, focusing on the events that will define the future of companies, products and therapy areas. Written by experienced journalists, EP Vantage provides timely financial analysis of regulatory and patent decisions, marketing approvals, licensing deals, and M&A, giving fresh angles and insight to both current and future industry triggers. EP Vantage is powered by EvaluatePharma, the industry leader in consensus forecasts.
I'm an Army veteran and former energy dividend writer for The Motley Fool. My goal is to help all people learn how to harness the awesome power of dividend growth investing to achieve their financial dreams, and enrich their lives. With 20 years of investing experience, I've learned what works and more importantly, what doesn't, when it comes to building long-term wealth and income streams. I'm currently on an epic quest to build a broadly diversified, high-quality, high-yield dividend growth portfolio that:
1. Pays 4-5% yield
2. Offers 9%-10% annual dividend growth
3. Pays dividends AT LEAST on a weekly, but preferably, daily basis
1. Navios Maritime Midstream Partners (NAP)
2. Golar LNG Partners (GMLP)
3. Dynagas LNG Partners (DLNG)
4. Suburban Propane Partners (SPH)
5. Ship Finance International (SFL)
6. KNOT Offshore Partners (KNOP)
7. Sunoco LP (SUN)
8. Summit Midstream Partners (SMLP)
9. Gaslog Partners (GLOP)
10. Triangle Capital (TCAP)
11. Seaspan (SSW)
12. CorEnergy Infrastructure Trust (CORR)
13. Energy Transfer Partners (ETP)
14. Fidus Investment Corp. (FDUS)
15. New Mountain Finance Corp. (NMFC)
16. Ares Capital (ARCC)
17. Annaly Capital Management (NLY)
18. Terra Nitrogen (TNH)
19. Monroe Capital (MRCC)
20. Hercules Capital (HGTC)
21. TPG Specialty Lending (TSLX)
22. Enviva Partners (EVA)
23. ONEOK Partners (OKS)
24. Hoegh LNG Partners (HMLP)
25. Jernigan Capital (JCAP)
26. Starwood Property Trust (STWD)
27. New Senior Investment Group (SNR)
28. Ladder Capital Corp. (LADR)
29. Compass Diversified Holdings (CODI)
30. Goldman Sachs BDC Inc (GSBD)
31. Ares Commercial Real Estate Corp. (ACRE)
32. AmeriGas Partners (APU)
33. Ciner Resources (CINR)
34. Care Capital Properties (CCP)
35. Genesis Energy Partners (GEL)
36. Landmark Infrastructure Partners (LMRK)
37. Blackstone Minerals (BSM)
38. Omega Healthcare Investors (OHI)
39. Tallgrass Energy Partners (TEP)
40. Xenia Hotels & Resorts (XHR)
41. Holly Energy Partners (HEP)
42. City Office REIT (CIO)
43. Gaming and Leisure Properties (GLPI)
44. Pattern Energy Group (PEGI)
45. Sunoco Logistics Partners (SXL)
46. Sabra Healthcare REIT (SBRA)
47. Community Healthcare Trust (CHCT)
48. Main street Capital (MAIN)
49. LaSalle Hotel Properties (LHO)
50. Energy Transfer Equity (ETE)
51. Chatham Lodging Trust (CLDT)
52. Royal Dutch Shell (RDS.A)
53. Chesapeake Lodging Trust (CHSP)
54. Macquarie Infrastructure Corp. (MIC)
55. MPLX (MPLX)
56. Medical Properties Trust (MPW)
57. Apple Hospitality REIT (APLE)
58. 8Point3 Energy Partners (CAFD)
59. Brookfield Renewable Partners (BEP)
60. Stag Industrial (STAG)
61. NRG Yield (NYLD)
62. InfraREIT (HIFR)
63. VEREIT (VER)
64. Armada Hoffler Properties (AHH)
65. Spirit Realty Capital (SRC)
66. HollyFrontier Corp. (HFC)
67. Vodafone (VOD)
68. Hannon Armstrong Sustainable Infrastructure Capital (HASI)
69. Ford (F)
70. NextEra Energy Partners (NEP)
71. GM (GM)
72. PacWest Bancorp (PACW)
73. AT&T (T)
74. Easterly Government Properties (DEA)
75. Brookfield Property Partners (BPY)
76. ONEOK Inc (OKE)
77. W.P Carey (WPC)
78. MGM Growth Properties (MGP)
79. Preferred Apartment Communities (APTS)
80. Hersha Hospitality Trust (HT)
81. RLJ Hospitality Trust (RLJ)
82. Enterprise Products Partners (EPD)
83. Pebblebrook Hotel Trust (PEB)
84. Brookfield Infrastructure Partners (BIP)
85. Magellan Midstream Partners (MMP)
86. Iron Mountain (IRM)
87. National Health Investors (NHI)
88. EPR Properties (EPR)
89. Spectra Energy Corp. (SE)
90. Lazard Ltd. (LAZ)
91. Chevron (CVX)
92. Helmerich & Payne (HP)
93. Valero Energy Corp (VLO)
94. Maiden Holdings (MHLD)
95. Oceaneering International (OII)
96. Toronto-Dominion Bank (TD)
97. Invesco (IVZ)
98. ExxonMobil (XOM)
99. L Brands (LB)
100. Suncor Energy (SU)
101. Wells Fargo (WFC)
102. Gilead Sciences (GILD)
103. Bank of America (BAC)
Kevin is a market enthusiast and individual investor focused on value investing and disruptive companies. He has spent 8 years in the consumer packaged goods industry and has nearly 20 years of individual investment experience.
Brian is the founder of Investor in the Family and Online Investor Conference.
At Investor in the Family (http://investorinthefamily.com/), Brian's goal is to help protect investors from making big mistakes that jeopardize their portfolios and financial futures.
The Online Investing Conference (http://onlineinvestingconference.com/) was created to help link self-directed investors with carefully filtered and proven investing professionals to help save investors both time and money while building a portfolio that outperforms.
If you'd like to connect or learn more, please feel free to send a private message via Seeking Alpha platform.
Zach is a biotech investor with PhD training in Biochemistry and Molecular Biology. In real life, he is a scientific writer specializing in continuing medical education. He hopes to provide a crucial piece of total due diligence as well as interesting insight into clinical findings that may impact readers' portfolios and lives.
Motto: I invest in undervalued (i.e. cheap) well-established companies trading at a below market multiple.
The companies that I invest in are large stable companies with proven track records. My goal is the highest total return possible with the least amount of risk.
Professional Background: I am a healthcare practitioner with extensive experience in the pharmaceutical sector. I have a passion for investing honed over the past twenty years through various market cycles.
Editor for The Biotech Forum (www.biotechforumsa.com), the #2 subscribed to Marketplace investment service offered through SeekingAlpha. Top 5% ranked analyst (TipRanks) 2013 through first half of 2015. Daily contributor for Real Money Pro. Hedge fund manager from 2008 to 2011. Previously technology executive at Fortune 100 firm for a decade. For Free weekly investment reports on small, attractive biotech stocks just register at www.bretjenseninvests.com
Over 10 years of experience as a sell side analyst covering Big Pharma names. Specialize in contrarian calls with a very good success rate. Now working as buy side analyst with a proprietary fund. A word of advise - Investment decisions are not an absolute science, and hence readers should use their own judgement to take a decision before investing.
I worked almost 30 years in the pharmaceutical industry. I started as a sales rep after earning my degree in biological sciences and (later) biomedical sciences. I then went back to school, got my MBA, and spent the following 20 years working up the ranks. I spent the latter parts of my career working as an analyst, meaning I would analyze data on 1,000s of compounds, collect reports from scientists, and then present the information to those who decided whether the candidates would go on to clinical trials (additional preclinical studies) or would be thrown to the dumpster for some small company to find and develop further. I have worked in just about every department in the pharmaceutical industry, including biotechnology, oncology, infectious disease, genetics, etc.
Now that I am recently retired, I have joined Seeking Alpha to share my knowledge of the healthcare industry, and discuss trends that I've seen throughout my career. I have chosen the task of managing my own retirement accounts, therefore Seeking Alpha has become a great interest to me.
I am hoping to learn and teach via Seeking Alpha. Also, my grandchildren call me Shennie so that's what I go by these days
Over 30 years of investing in individual stocks. Extensive business experience with small to mid-size companies, including as CEO. Many hundreds of blog posts on financial and economic matters since 2008. Focus on value with catalysts for upside price action. Background as a physician and pharmaceutical inventor and entrepreneur, however focus now is global and involves almost all economic categories.
Lowenthal Capital Partners (LCP) has joined Arrow Loop Research to deliver a value-based investing newsletter called Arrow Loop Research's Actionable Ideas for Maximizing Returns. Sign up for a free trial here.
LCP is operated by Trevor Lowenthal. Trevor graduated with a BA in Political Science from University of California, Davis with Summa Cum Laude distinction. Trevor is finishing his J.D. at the University of Colorado Boulder Law School.
Arrow Loop Research formed as a partnership between LCP, Dr. Paul Price, and Market Shadows (Paul is a managing partner of Market Shadows.)
Paul writes about stocks, options and the market every weekday on Real Money Pro, a subscription site on TheStreet.com. Paul has been a speaker at the International Traders Expo in New York City and the Options and Forex Expo in Las Vegas. He also gives investment seminars for subscribers of TheStreet's multiple subscription sites. Dr. Price is a featured contributor on Market Shadows.com, GuruFocus.com and TalkMarkets.com.
Paul followed his passion for the stock market when he gave up his career as a dentist to join Merrill Lynch back in April of 1987. Paul feels that he is “living the dream” of many investors. He stopped “going to work” when he turned 50 (in the year 2000) and has been living well from his investment returns ever since.
Paul enjoys sharing the accumulated market wisdom he’s gained from years in the markets. He loves analyzing companies and picking individual stocks. According to Paul, once you know what equities to buy, option writing (selling covered calls and/or naked puts) just flows naturally. They serve as ways to impose investment discipline and create income while providing an extra margin of safety versus plain vanilla share ownership. Paul’s articles stand out for their unique graphics which are packed with information which distills our TMI (too much information) world into easy to understand, and actionable advice.
Having always been a learning machine, I speak five languages, have worked as a sales agent, project manager, translator, computer consultant, software engineer, built a house with my own hands, published books and essays on literature, philosophy and art, have written for magazines of various kinds in different countries.
After retiring early in 2004, little by little, I have become a fund manager for some friends and myself, following the principles of value investing laid out by Benjamin Graham, Phil Fisher, Charlie Munger and Warren Buffett. You can read about my thoughts on a suitable portfolio structure for early retirees here.
My articles should not be considered to be any kind of investment advice. What suits me well is not necessarily good for others, as successful investing is somewhat like a marriage: If only one is perfect, the marriage won’t work. So please do your own research and remember Benjamin Graham's advice: “The investor’s chief problem — and even his worst enemy — is likely to be himself.”
I sincerely hope that my readers will ignore the Performance calculations provided by Seeking Alpha (although only to Pro subscribers, I believe). For reasons unknown to me, some of my European stock picks seem to be tracked inaccurately by Seeking Alpha's system. Spin-offs are not included in total return calculations and many of my correction requests didn't receive any answer at all. Moreover, my time frame almost never is as short as only 1 year (the maximum included in Seeking Alpha's table) and personally I consider the 1 year performance of my stock picks to be close to meaningless.
Over seven years of experience making contrarian bets based on my macro view and stock-specific turnaround stories to garner outsized returns with a favorable risk/reward profile. If you want me to cover a specific stock or have a question for an article, just let me know!
I focus on investments in the oil & gas & MLP sectors with an eye for dividend income growth and long-term capital appreciation. I typically allocate a portion of my own portfolio and devote some of my Seeking Alpha articles to small and medium sized companies offering compelling risk/reward propositions. I am an engineer, not a qualified investment advisor. While the information and data presented in my articles are obtained from company documents and/or sources believed to be reliable, they have not been independently verified. Therefore, I cannot guarantee its accuracy. I advise investors conduct their own research and/or consult a qualified investment advisor. I explicitly disclaim any liability that may arise from investment decisions you make based on my articles. Thanks for reading and I wish you much success with your investments.
I am a simple individual investor who believes that the playing field is level, but may require active management of one's holdings.
I've devised a series of steps that constitute a highly defined covered option strategy that most anyone can follow and that I've described in Option to Profit (2011).
Having retired from a career in Pediatric Dentistry, approximately 10 years ahead of schedule, after spending the previous 10 years working just 2 days each week, I now spend my time trading and alerting others of trading opportunities in large cap positions through the Option to Profit subscription service, a premium subscription service that provides actionable Trading Alerts via text messaging or e-mail at www.optiontoprofit.com. as well as a Web site access only subscription plan.
The Option to Profit subscription service is now in its 4th year.
Now, the Web Access subscription plan is available through Seeking Alpha's "Marketplace." A listing of those articles can be found at https://seekingalpha.com/account/research/subscribe?slug=george-acs
The subscription through Seeking Alpha also includes access to the full Option to Profit web mirror site at http://sa.optiontoprofit.com.
I want you to join me in making your stock portfolio improve the quality of your life. Whatever stage of life you are in, you can make your stocks improve that quality by putting them to work for you.
Onuora Amobi is the CEO of Learn About The Web Inc. Onuora has more than a decade of information security, project management and management consulting experience. He has specialized in the management and deployment of large scale ERP client/server systems.
In addition, he has shown leadership in positions that have ranged from from consultant to Principal/Director. His work history includes postitions at VERITAS Software, Deloitte & Touche (now Deloitte Consulting), EDS Enterprise Solutions, IBM, Kaiser Permanente and Warner Bros Studios among others.
In 2002, he made the switch from Information Technology to Online Marketing and in 2008 started Nnigma, a Pasadena based online marketing company.
In addition to building their own profitable web sites, they specialize in helping corporate clients create and refine their brand, message and web presence.
In addition to being a former MVP and the founder and editor of EyeonWindows.com and the Las Vegas Travel Guide (http://www.las-vegastravelguide.com), he is the CEO of a Pasadena based online marketing education startup - Learn About The Web Inc. (www.learnabouttheweb.com)
With over 8 years in the medical field, and 4 years serving the U.S. Army's Medical Corp, I have a large interest, and unique insight into the financial future of the healthcare field.
It is my intent to consider and dissect the newest 'up and coming' technology from a health care providers point of view.
I will provide all of the facts necessary to make actionable decisions, with the utmost integrity.
Over 15 years as an IT Consultant for a wide range of clients including Dell, Ingram Micro, BankAm South and FedEx Data Center. Specializes in technology, contrarian plays and global macro. My articles have appeared on Morningstar.com, IHIQS, Seeking Alpha, Yahoo! Finance, MarketWatch, EIN Newsdesk, Google Finance, Motley Fool, MSN Money, and AOL Daily Finance.
Author of the critically acclaimed book, "Taking Charge With Value Investing (McGraw-Hill, 2013)" and the premium subscription service "Tipping The Scale" (as seen below). An analyst that ranks in the top 4% on both tipranks.com and Motley Fool CAPS for stock picking performance.
Tipping the Scale members gain access to the TTS Portfolio Tracker. Here, members see what I am buying and selling the minute it happens, along with what I have owned, bought, and sold historically. These are just a few of the features on the TTS Portfolio Tracker.
Tipping The Scale is an equity research platform that uses a numeric scale instead of the traditional "Buy, Hold, Sell" to identify the best investment opportunities in the market. Stock coverage is determined by market catalyst, and every company goes through a vigorous test in 10 different categories. The higher the total score, the bigger the upside. In addition, Tipping the Scale also provides a number of portfolio strategies to hedge the volatility of the market and protect from downside.
Check out my instablog for more information on the popular research service Tipping the Scale, including performance information, benefits, and how it all works.
Brendan, a Pennsylvanian by birth, completed his B.S. at Allegheny College and his Ph.D. at Stanford University in the field of organic synthesis. He has been employed by a major pharmaceutical company and a tiny biopharma startup, but is an avid investor as well. His writings focus on a variety of topics ranging from stocks and bonds to analysis of recent news events relevant to financial markets.
Author Bio: Andrew Sachais’ focus is on analyzing markets with global macro-based strategies. He is a former hedge fund trader and has written for TheStreet.com and was an economist for Minyanville. Sachais takes into consideration global equity, commodity, currency and debt markets, and is a recent graduate of Georgetown University, where he earned a degree in Economics. He currently runs an event-driven macro fund.